Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer
10 Mai 2023 - 10:05PM
Nyxoah Appoints
Christoph
Eigenmann as Chief
Commercial Officer
Mont-Saint-Guibert, Belgium –
May
10,
2023,
10:05pm
CET /
4:05pm
ET – Nyxoah SA
(Euronext Brussels/Nasdaq:
NYXH) (“Nyxoah” or the “Company”), a medical technology
company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today
announced the appointment of Christoph Eigenmann as Chief
Commercial Officer. Christoph will oversee commercial activities
globally, be responsible for sales and marketing in existing
markets, and new market development.
Christoph brings a wealth of experience in
medical technologies to Nyxoah. He spent over 20 years with Johnson
& Johnson (J&J), where he oversaw commercial organizations
in various geographies in Europe and the United States. He has
extensive experience in managing orthopedic and neuro businesses in
the German, Swiss and U.S. markets, including as Senior Vice
President, Sales & Marketing for J&J’s close to $1B U.S.
Spine franchise, and has led regional functions across EMEA and
North America. Christoph holds a master’s degree in chemical
engineering and biotechnology from the Swiss Federal Institute of
Technology in Lausanne, Switzerland.
“We are excited to have Christoph join Nyxoah as
we embark on our next phase of growth. Christoph's years of
experience in commercializing medical devices globally will be
invaluable as Nyxoah prepares to enter the U.S. market and expands
its commercial presence internationally,” commented Olivier
Taelman, Nyxoah Chief Executive Officer.
“I am thrilled to be joining Nyxoah at this
critical and exciting time. Hypoglossal nerve stimulation is a
large and highly under-penetrated market, and Nyxoah’s novel
approach provides a highly differentiated solution for patients,
clinicians, and healthcare systems. I look forward to applying my
long tenure of commercializing medical devices in the U.S. to
ensuring Genio becomes a standard of care in OSA treatment,” added
Christoph.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Following the positive outcomes of the BETTER SLEEP study, Nyxoah
received CE mark approval for the expansion of its therapeutic
indications to Complete Concentric Collapse (CCC) patients,
currently contraindicated in competitors’ therapy. Additionally,
the Company is currently conducting the DREAM IDE pivotal study for
FDA and U.S. commercialization approval.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Contacts:NyxoahDavid
DeMartino, Chief Strategy Officerdavid.demartino@nyxoah.com+1 310
310 1313
- ENGLISH_CCO Appointment_FINAL
Nyxoah (EU:NYXH)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Nyxoah (EU:NYXH)
Historical Stock Chart
Von Mai 2023 bis Mai 2024